[go: up one dir, main page]

WO2014193999A3 - Biomarker methods and compositions - Google Patents

Biomarker methods and compositions Download PDF

Info

Publication number
WO2014193999A3
WO2014193999A3 PCT/US2014/039858 US2014039858W WO2014193999A3 WO 2014193999 A3 WO2014193999 A3 WO 2014193999A3 US 2014039858 W US2014039858 W US 2014039858W WO 2014193999 A3 WO2014193999 A3 WO 2014193999A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
condition
stages
biomarkers
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/039858
Other languages
French (fr)
Other versions
WO2014193999A2 (en
Inventor
Robert T MANEY
Tassilo HORNUNG
Daniel A. Holterman
David Spetzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caris Science Inc
Original Assignee
Caris Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris Science Inc filed Critical Caris Science Inc
Publication of WO2014193999A2 publication Critical patent/WO2014193999A2/en
Publication of WO2014193999A3 publication Critical patent/WO2014193999A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease, select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and to determine treatment efficacy. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as microvesicles, and nucleic acid-protein complexes.
PCT/US2014/039858 2013-05-28 2014-05-28 Biomarker methods and compositions Ceased WO2014193999A2 (en)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US201361828110P 2013-05-28 2013-05-28
US61/828,110 2013-05-28
US201361838762P 2013-06-24 2013-06-24
US61/838,762 2013-06-24
US201361841683P 2013-07-01 2013-07-01
US61/841,683 2013-07-01
US201361843256P 2013-07-05 2013-07-05
US61/843,256 2013-07-05
US201361862809P 2013-08-06 2013-08-06
US61/862,809 2013-08-06
US201361863828P 2013-08-08 2013-08-08
US61/863,828 2013-08-08
US201361866014P 2013-08-14 2013-08-14
US61/866,014 2013-08-14
US201361867978P 2013-08-20 2013-08-20
US61/867,978 2013-08-20
US201361871107P 2013-08-28 2013-08-28
US61/871,107 2013-08-28
US201361874621P 2013-09-06 2013-09-06
US61/874,621 2013-09-06

Publications (2)

Publication Number Publication Date
WO2014193999A2 WO2014193999A2 (en) 2014-12-04
WO2014193999A3 true WO2014193999A3 (en) 2015-02-05

Family

ID=51989523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/039858 Ceased WO2014193999A2 (en) 2013-05-28 2014-05-28 Biomarker methods and compositions

Country Status (1)

Country Link
WO (1) WO2014193999A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108982846A (en) * 2018-08-03 2018-12-11 华中科技大学同济医学院附属协和医院 The detection method of glioma related mesenchymal stem cell subgroup biological nature

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
KR20170138534A (en) 2015-04-21 2017-12-15 엔리벡스 테라퓨틱스 리미티드 Therapeutically Administered Blood Apoptosis Cell Preparations and Uses Thereof
CN104931698B (en) * 2015-05-17 2016-06-22 济南大学 The preparation method of a kind of stomach cancer marker gold nanoclusters Electrochemiluminescsensor sensor based on NP-NiGdAu and application
CA2991045A1 (en) 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides binding c1q
AU2016298317B2 (en) 2015-07-28 2021-02-18 Caris Science, Inc. Targeted oligonucleotides
CN106442990B (en) * 2015-08-06 2018-07-27 中国人民解放军军事医学科学院生物医学分析中心 System for predicting Lung Squamous Carcinoma Patients prognosis
WO2017079537A1 (en) * 2015-11-04 2017-05-11 Duke University Polycationic polymers for use in treating and detecting cancer
KR20180110141A (en) 2016-02-18 2018-10-08 엔리벡스 테라퓨틱스 리미티드 Combination of immunotherapy and cytokine regulating therapy to treat cancer
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
CN105969889B (en) * 2016-07-06 2019-04-19 四川省人民医院 Use of MUC3B gene SNP site
US20190153427A1 (en) * 2016-07-08 2019-05-23 President And Fellows Of Harvard College Determination of rna in blood or other fluids
BR102016018150A2 (en) * 2016-08-04 2018-03-06 Fundação Universidade Federal De São Carlos ADAM10 BIOMARCATOR DETECTION DEVICE FOR ALZHEIMER DISEASE DIAGNOSIS, APPLICATION METHOD OF USE OF THIS DEVICE, USE OF ALZHEIMER DISEASE DIAGNOSTIC DEVICE DIAGNOSIS METHOD OF APPLICATION
CN107875140A (en) * 2016-09-30 2018-04-06 复旦大学 A kind of double targeted drug delivery systems and its application in oncotherapy preparation is prepared
CN106520926A (en) * 2016-10-14 2017-03-22 浙江大学 A kind of primer sets and detection method for detecting cancer of pancreas
CN106383104A (en) * 2016-11-07 2017-02-08 百奥森（江苏）食品安全科技有限公司 Anti-interference rapid detection kit for bioluminescence microbial population
WO2018102162A1 (en) * 2016-11-30 2018-06-07 Exosome Diagnostics, Inc. Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients
KR102014951B1 (en) 2017-01-06 2019-08-27 강원대학교산학협력단 Biomarker, kit or composition for detecting cancer caused by inhibition of transcriptional activity of p53, method for providing information or screening drugs, and malignant transformation model
US11830583B2 (en) * 2017-01-06 2023-11-28 Mantra Bio Inc. Systems and methods for characterizing extracellular vesicle (EV) population by predicting whether the EV originates from B, T, or dendritic cells
CN106868146B (en) * 2017-03-06 2020-01-24 新乡医学院 Primers, kits, methods and applications for detecting miRNA expression associated with vincristine resistance in colorectal cancer
CN106645757B (en) * 2017-03-13 2019-01-15 新疆医科大学 A kind of serum protein markers group and its application diagnosing early onset diabetes MODY
CN106987649A (en) * 2017-05-31 2017-07-28 上海博慷生物科技有限公司 A kind of primer sets and detection method for being used to detect glioma
CN111108388A (en) * 2017-06-23 2020-05-05 昂西免疫德国有限公司 Immunooncology for treating cancer
JP7285215B2 (en) * 2017-06-30 2023-06-01 国立研究開発法人医薬基盤・健康・栄養研究所 Biomarkers for detecting colorectal cancer
AU2018315056B2 (en) * 2017-08-08 2021-06-17 Queensland University Of Technology Methods for diagnosis of early stage heart failure
CN107643403A (en) * 2017-08-30 2018-01-30 福建师范大学 Application of the IGFBP2 in preparing nervus gastrica endocrine cancer Postoperative determination and assessing kit
US20200256862A1 (en) * 2017-10-23 2020-08-13 Massachusetts Institute Of Technology Functionalized solid support
CN108680750A (en) * 2017-12-29 2018-10-19 广西壮族自治区人民医院 The ELISA detection method and kit of TROP2 expressing quantities
AU2019290743A1 (en) * 2018-06-21 2021-01-21 China Medical University Biomarkers for urothelial carcinoma and applications thereof
US20210310008A1 (en) * 2018-08-07 2021-10-07 The Regents Of The University Of Colorado, A Body Corporate Parn as a biomarker and therapeutic target
CN109112106B (en) * 2018-09-07 2022-01-04 广州长峰生物技术有限公司 Method for establishing in vitro model of human primary liver cancer tissue
CN109197781B (en) * 2018-09-14 2021-04-06 徐州医科大学 Construction of AURKA-CKO1-N Conditional Gene Knockout Mouse Model
CN109387411B (en) * 2018-10-12 2020-01-10 吉林大学 Method for detecting biological available lead in soil
CN109529051A (en) * 2018-12-10 2019-03-29 大连医科大学 Saliva acyltransferase recombinant plasmid and its with pemetrexed preparation inhibit bladder cancer proliferation and invasion drug in application
WO2020123604A1 (en) * 2018-12-11 2020-06-18 Rensselaer Polytechnic Institute Use of multivariate analysis to assess treatment approaches
JP7317379B2 (en) * 2019-01-04 2023-07-31 国立大学法人京都大学 Examination method for ulcerative colitis and primary sclerosing cholangitis
CN109825579B (en) * 2019-01-23 2020-01-14 山东大学齐鲁医院 Application of GALNT2 as biomarker in glioma diagnosis and/or treatment
WO2020163591A1 (en) * 2019-02-06 2020-08-13 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for characterizing pancreatic ductal adenocarcinoma
EP3924972A4 (en) * 2019-02-14 2023-03-29 Mirvie, Inc. METHODS AND SYSTEMS FOR DETERMINING A PREGNANCY-ASsociated CONDITION OF AN INDIVIDUAL
CN111197093A (en) * 2019-02-28 2020-05-26 北京市动物疫病预防控制中心 LAMP (loop-mediated isothermal amplification) detection primer group, kit and method for echinococcus caninum
CN109828029B (en) * 2019-03-28 2021-08-27 烟台中凯检测科技有限公司 Ultrasonic phased array detection system and method based on original data
CN110412273B (en) * 2019-06-26 2022-09-09 四川大学华西医院 Application of CAAP1 autoantibody detection reagent in preparation of lung cancer screening kit
CN110412281B (en) * 2019-06-26 2022-09-09 四川大学华西医院 Application of BEGAIN autoantibody detection reagent in preparation of lung cancer screening kit
CN114502189A (en) * 2019-07-19 2022-05-13 安特卫普大学 Mucin isoforms in diseases characterized by barrier dysfunction
CN110501501B (en) * 2019-07-23 2021-06-04 武汉大学 Application and kit of tumor markers for early diagnosis of lung cancer
CN110488018A (en) * 2019-07-31 2019-11-22 四川大学华西医院 PPM1F autoantibody detection reagent is preparing the purposes in screening lung cancer kit
CN110501507B (en) * 2019-07-31 2020-09-25 四川大学华西医院 Use of RPS6KA1 autoantibody detection reagent in the preparation of lung cancer screening kit
KR102055872B1 (en) 2019-08-20 2019-12-13 강원대학교산학협력단 Biomarker, kit or composition for detecting cancer caused by inhibition of transcriptional activity of p53, method for providing information or screening drugs, and malignant transformation model
CN110551809A (en) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 Application of miR-124 in spinal cord injury repair
CN114651002B (en) * 2019-11-07 2024-12-13 武汉华大吉诺因生物科技有限公司 Tumor-specific peptide sequences and their applications
CN110819717A (en) * 2019-12-02 2020-02-21 上海速创诊断产品有限公司 Graphene oxide-containing amplification system and application thereof in colorectal cancer marker detection
KR102168498B1 (en) 2019-12-09 2020-10-21 강원대학교산학협력단 Biomarker, kit or composition for detecting cancer caused by inhibition of transcriptional activity of p53, method for providing information or screening drugs, and malignant transformation model
WO2021163608A2 (en) * 2020-02-14 2021-08-19 Galaxy Ccro, Inc. Devices and methods for treating ischaemia and acute respiratory distress syndromes
EP4107528A4 (en) * 2020-03-30 2024-04-03 RJS Mediagnostix Method and system for diagnosis and management of gastroesophageal diseases
CN111733140B (en) * 2020-04-04 2022-07-01 华中农业大学 Hybridoma cell line against canine matrix metalloproteinase and preparation method thereof, monoclonal antibody and application thereof
CN111323604B (en) * 2020-04-14 2023-04-07 郑州大学第一附属医院 Cardiac adenocarcinoma prognosis prediction marker and application thereof
CN111735946B (en) * 2020-05-22 2023-07-07 首都医科大学附属北京友谊医院 Serum ALDH1B1 autoantibody quantitative detection kit and application thereof
CN111489829A (en) * 2020-05-29 2020-08-04 杭州广科安德生物科技有限公司 Method for constructing mathematical model for detecting pancreatic cancer in vitro and application thereof
CN111850108B (en) * 2020-06-05 2023-09-05 广东省人民医院 DNA methylation composition related to death risk in patients with coronary heart disease, screening method and application thereof
WO2021259162A1 (en) * 2020-06-22 2021-12-30 四川百利药业有限责任公司 Anti-trop2 antibody
US20210393536A1 (en) * 2020-06-23 2021-12-23 Board Of Regents, The University Of Texas System Methods and compositions related to extracellular vesicles
CN112540176B (en) * 2020-07-08 2021-09-28 深圳霁因生物医药转化研究院 Kit, method and computer-readable storage medium for diagnosing diseases associated with FAP expression abnormality
IL301664A (en) * 2020-10-05 2023-05-01 Gina Life Diagnostics Ltd Identification and characterization of specific biomarkers for ovarian cancer in vaginal secretions
KR102185037B1 (en) 2020-10-14 2020-12-01 강원대학교산학협력단 Biomarker, kit or composition for detecting cancer caused by inhibition of transcriptional activity of p53, method for providing information or screening drugs, and malignant transformation model
CN112255408B (en) * 2020-10-16 2023-04-14 牡丹江医学院 A tumor biomarker and tumor detection kit
CN112362871B (en) * 2020-10-21 2023-06-06 杭州凯保罗生物科技有限公司 Biomarker for esophageal cancer and application thereof
KR102205224B1 (en) 2020-11-24 2021-01-20 강원대학교산학협력단 Biomarker, kit or composition for detecting cancer caused by inhibition of transcriptional activity of p53, method for providing information or screening drugs, and malignant transformation model
KR102221671B1 (en) 2021-01-13 2021-03-02 강원대학교산학협력단 Biomarker, kit or composition for detecting cancer caused by inhibition of transcriptional activity of p53, method for providing information or screening drugs, and malignant transformation model
CN112646895A (en) * 2021-01-22 2021-04-13 深圳科诺医学检验实验室 Primer, probe, kit, detection method and application for detecting gene expression level
KR102243705B1 (en) 2021-02-22 2021-04-23 강원대학교산학협력단 Biomarker, kit or composition for detecting cancer caused by inhibition of transcriptional activity of p53, method for providing information or screening drugs, and malignant transformation model
KR102260250B1 (en) 2021-02-22 2021-06-03 강원대학교산학협력단 Biomarker, kit or composition for detecting cancer caused by inhibition of transcriptional activity of p53, method for providing information or screening drugs, and malignant transformation model
TW202321465A (en) * 2021-08-06 2023-06-01 大陸商江蘇鵾遠生物技術有限公司 A tumor evaluation method and application thereof
CN113718032B (en) * 2021-09-08 2023-08-25 河北医科大学第二医院 Application of biomarkers in early detection of cervical cancer
CN113820497B (en) * 2021-09-23 2024-11-01 中国科学技术大学 Senile glial cell related biomarker and application thereof in diagnosis of Alzheimer's disease
CN115097137A (en) * 2021-11-11 2022-09-23 北京大学 A screening method, application and kit for disease-related markers
CN114438191B (en) * 2022-01-27 2024-04-30 宁波大学 Application of hypoxia-inducible factor-1α as a marker in the diagnosis of relapse of depression
CN114410773B (en) * 2022-01-27 2024-05-03 宁波大学 Marker combination for predicting or diagnosing depression recurrence and application thereof
CN114441760B (en) * 2022-04-07 2022-06-21 中国人民解放军军事科学院军事医学研究院 Biomarker and kit for liver cancer diagnosis and detection method
CN114705859B (en) * 2022-04-26 2023-02-24 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Biomarker for diagnosis, treatment and prognosis of liver cancer bone metastasis and application thereof
CN114944230A (en) * 2022-06-06 2022-08-26 复旦大学附属中山医院 A prognostic model of liver cancer based on three blood test indicators
CN115418403A (en) * 2022-08-24 2022-12-02 中国医学科学院北京协和医院 Method and reagent for diagnosing pancreatic cystic tumor
CN115407068B (en) * 2022-09-20 2024-07-12 华中科技大学同济医学院附属协和医院 Application of OMA1 protein as glioma marker and kit thereof
CN115616214A (en) * 2022-09-20 2023-01-17 湖南中医药大学 Application and kit of SOX10 antibody
CN116640845A (en) * 2022-11-28 2023-08-25 复旦大学附属中山医院 Primer group for rapidly analyzing CTC biomarker and application thereof
CN116358954B (en) * 2023-02-22 2024-08-09 深圳市昭蓝生物科技有限公司 Composite quality control product, preparation method thereof and prenatal screening kit
WO2024239003A2 (en) * 2023-05-17 2024-11-21 Nexosome Oncology Llc Biomarkers for cancer detection
CN116930298B (en) * 2023-09-14 2023-12-26 古镜科技(深圳)有限公司 Electrochemical biosensor for detecting HIV, and preparation method and application thereof
WO2025092877A1 (en) * 2023-11-01 2025-05-08 The University Of Hong Kong A method of multi-biomedical markers association for nasopharngeal carcinoma metastatses
CN117165677A (en) * 2023-11-03 2023-12-05 首都儿科研究所 Application of detection biomarker in preparation of products for neural tube malformation diseases
CN118910065B (en) * 2024-08-22 2025-07-25 中国人民解放军军事科学院军事医学研究院 Sequence and detection method of oligonucleotide aptamer for specifically recognizing radiation-sensitive protein CDKN1A
CN119574890B (en) * 2025-01-03 2025-05-23 中国人民解放军军事科学院军事医学研究院 Application of the combination of FGGY, DSG1 and CUSTOS proteins in the prognosis of pancreatic neuroendocrine tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012174282A2 (en) * 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
US20130045490A1 (en) * 2010-02-12 2013-02-21 Kagoshima University Antibody against mucin 1 (muc1) protein and use of same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045490A1 (en) * 2010-02-12 2013-02-21 Kagoshima University Antibody against mucin 1 (muc1) protein and use of same
WO2012174282A2 (en) * 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108982846A (en) * 2018-08-03 2018-12-11 华中科技大学同济医学院附属协和医院 The detection method of glioma related mesenchymal stem cell subgroup biological nature
CN108982846B (en) * 2018-08-03 2022-02-08 华中科技大学同济医学院附属协和医院 Detection method of biological characteristics of glioma-related mesenchymal stem cell subsets

Also Published As

Publication number Publication date
WO2014193999A2 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
WO2014193999A3 (en) Biomarker methods and compositions
WO2012174282A3 (en) Biomarker compositions and methods
WO2013134786A3 (en) Biomarker compositions and methods
WO2013022995A3 (en) Biomarker compositions and methods
WO2010056337A3 (en) Methods and systems of using exosomes for determining phenotypes
Boyapati et al. Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications
BR112013031591A2 (en) circulation biomarkers for cancer
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
MX2025006655A (en) Methods for determining dpp3 and therapeutic methods
WO2013033074A3 (en) Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
EA201400117A1 (en) METHODS AND NUCLEIC ACIDS FOR DETERMINATION OF THE PREDICTION IN CANCER PATIENTS
WO2014028862A9 (en) Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias
HK1255533A1 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
EP3186397A4 (en) Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
EA201590024A1 (en) METHODS FOR IDENTIFYING DISEASES OR CONDITIONS WITH THE APPLICATION OF CIRCULATING PATIOUS CELLS
WO2015014903A3 (en) Diagnostic tools for alzheimer's disease
EA201792669A1 (en) IGFBP3 AND ITS APPLICATION
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
WO2015013508A3 (en) Methods for diagnosing and treating immune disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14803421

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14803421

Country of ref document: EP

Kind code of ref document: A2